By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Diazon Pharma 

1010 Sherbrooke Street West
Suite 408
Montreal   Quebec  H3A 2R7  Canada
Phone: 514-564-6474 Fax: n/a


SEARCH JOBS

Embedded in its novel mechanism of action, Diazon’s new generation onco-therapeutic DZ-2384 targets a proven therapeutic pathway in oncology, but one whose potential in modern cancer therapy has been severely restricted due to unacceptable toxicities. DZ-2384 overcomes this restriction by modulating microtubule structure and dynamics in a distinct way, delivering potent anti-tumor efficacy with an unusually superior safety profile, including lack of neurotoxicity in preclinical models – qualities that are widely sought by clinicians. In addition to replacing the current drugs that target microtubules, Diazon believes that DZ-2384 has the potential to safely combine with targeted therapeutics, including immunotherapies.

YEAR FOUNDED:

2013

LEADERSHIP:

Founders: Patrick Harran, Gordon Shore and Anne Roulston

CFO: Michael Dixon

CSO: Gordon Shore

CDO: Louise Proulx

PRODUCTS:

All Products


Key Statistics


Email:
Ownership: Private

Web Site: Diazon Pharmaceuticals
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
//-->